Evofem Biosciences, Inc. (EVFM): Price and Financial Metrics

Evofem Biosciences, Inc. (EVFM): $0.70

0.00 (-0.34%)

POWR Rating

Component Grades













Add EVFM to Watchlist
Sign Up

Industry: Biotech


of 508

in industry


  • Growth is the dimension where EVFM ranks best; there it ranks ahead of 59.27% of US stocks.
  • The strongest trend for EVFM is in Momentum, which has been heading down over the past 52 weeks.
  • EVFM's current lowest rank is in the Quality metric (where it is better than 0.31% of US stocks).

EVFM Stock Summary

  • Revenue growth over the past 12 months for Evofem Biosciences Inc comes in at 664.13%, a number that bests 98.72% of the US stocks we're tracking.
  • In terms of volatility of its share price, EVFM is more volatile than 99.39% of stocks we're observing.
  • Evofem Biosciences Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -97.13%, greater than the shareholder yield of merely 2.41% of stocks in our set.
  • Stocks that are quantitatively similar to EVFM, based on their financial statements, market capitalization, and price volatility, are BIOC, AQB, XERS, NISN, and CYRX.
  • Visit EVFM's SEC page to see the company's official filings. To visit the company's web site, go to www.evofem.com.

EVFM Valuation Summary

  • In comparison to the median Healthcare stock, EVFM's price/sales ratio is 255.95% higher, now standing at 40.4.
  • EVFM's price/sales ratio has moved NA NA over the prior 83 months.
  • EVFM's price/sales ratio has moved NA NA over the prior 83 months.

Below are key valuation metrics over time for EVFM.

Stock Date P/S P/B P/E EV/EBIT
EVFM 2021-08-31 40.4 15.4 -0.9 -1.0
EVFM 2021-08-30 35.7 13.6 -0.8 -0.9
EVFM 2021-08-27 36.4 13.8 -0.8 -0.9
EVFM 2021-08-26 36.2 13.8 -0.8 -0.9
EVFM 2021-08-25 37.8 14.4 -0.9 -1.0
EVFM 2021-08-24 32.7 12.4 -0.7 -0.9

EVFM Growth Metrics

  • The 2 year net income to common stockholders growth rate now stands at -6.58%.
  • Its 5 year net cashflow from operations growth rate is now at -64.32%.
  • Its year over year price growth rate is now at -76.72%.
Over the past 67 months, EVFM's revenue has gone up $3,408,000.

The table below shows EVFM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 3.408 -162.936 -150.074
2021-03-31 1.551 -124.411 -169.314
2020-12-31 0.446 -104.829 -142.309
2020-09-30 0.278 -79.196 -114.428
2020-06-30 0 -57.799 -98.327
2020-03-31 0 -62.295 -81.111

EVFM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EVFM has a Quality Grade of F, ranking ahead of 0.31% of graded US stocks.
  • EVFM's asset turnover comes in at 0.032 -- ranking 349th of 680 Pharmaceutical Products stocks.
  • EVOK, ARMP, and AGRX are the stocks whose asset turnover ratios are most correlated with EVFM.

The table below shows EVFM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.032 0.468 -3.756
2021-03-31 0.014 0.372 -6.609
2020-12-31 0.005 -0.049 -10.499
2020-09-30 0.004 -0.140 -65.377
2020-06-30 0.000 NA 23.332
2020-03-31 0.000 NA 10.597

EVFM Price Target

For more insight on analysts targets of EVFM, see our EVFM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.40 Average Broker Recommendation 1.5 (Moderate Buy)

EVFM Stock Price Chart Interactive Chart >

Price chart for EVFM

EVFM Price/Volume Stats

Current price $0.70 52-week high $5.53
Prev. close $0.70 52-week low $0.65
Day low $0.69 Volume 1,588,092
Day high $0.70 Avg. volume 6,608,918
50-day MA $0.76 Dividend yield N/A
200-day MA $1.58 Market Cap 108.65M

Evofem Biosciences, Inc. (EVFM) Company Bio

Evofem Biosciences, formerly Neothetics, develops and anticipates commercializing innovative products to address unmet needs in women's sexual and reproductive health. Its lead candidate is Amphora, a non-hormonal, surfactant-free bioadhesive vaginal gel designed for on-demand use as needed or desired by a woman. This investigational new drug is being developed as an on-demand, non-hormonal vaginal contraceptive and for the prevention of certain sexually transmitted infections (STIs). Data from a confirmatory Phase 3 clinical trial of Amphora for the prevention of pregnancy are expected in late 2018/early 2019. A Phase 2b/3 clinical trial of Amphora for the prevention of urogenital chlamydia and gonorrhea in women is also underway. Amphora received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the prevention of urogenital chlamydia in women, and is designated as a Qualified Infectious Disease Product (QIDP) by the U.S. Food & Drug Administration for the prevention of urogenital gonorrhea infection in women. The Company's second multipurpose prevention technology (MPT) vaginal gel candidate has QIDP designation for the reduction of reoccurrence of bacterial vaginosis. These designations may enable Evofem Biosciences to more rapidly evaluate and make these drugs available to women at risk of these infections.

EVFM Latest News Stream

Event/Time News Detail
Loading, please wait...

EVFM Latest Social Stream

Loading social stream, please wait...

View Full EVFM Social Stream

Latest EVFM News From Around the Web

Below are the latest news stories about Evofem Biosciences Inc that investors may wish to consider to help them evaluate EVFM as an investment opportunity.

"House Rules" Delivers Strong Initial Results and Drives Phexxi Growth

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced significant initial results of "House Rules," its national direct-to-consumer (DTC) campaign with celebrity spokeswoman Annie Murphy, aimed at broadening awareness and driving uptake of its hormone-free contraceptive, Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel.

Yahoo | October 20, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, investor!

William White on InvestorPlace | October 12, 2021

Evofem Biosciences Announces $10 Million Registered Direct Offering of Series B Preferred Stock

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it has entered into a definitive agreement with Keystone Capital Partners ("Keystone Capital") providing for the issuance and sale of an aggregate of 10,000 shares of Series B Convertible Stock in a registered direct offering for a purchase price of $1,000.00 per share. The aggregate gross proceeds from this offering are expected to be an aggregate of approximately $10.0 million, before deducting estimated offering expenses payable by

Yahoo | October 12, 2021

Evofem Biosciences Commends House of Representatives Leaders for Action to Ensure Coverage for the Full Range of Contraceptives Under ACA

Evofem Biosciences, Inc., (NASDAQ: EVFM) today commented on a letter from leaders in the House of Representatives to senior Biden Administration officials calling for action to ensure coverage for the full range of contraceptives under the Affordable Care Act (ACA).

Yahoo | October 8, 2021

Evofem Biosciences to Present at LD Micro Investor Conference on October 12, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at the 14th annual LD Micro Main Event being held in Los Angeles on October 12-14, 2021.

Yahoo | September 30, 2021

Read More 'EVFM' Stories Here

EVFM Price Returns

1-mo -9.94%
3-mo -20.60%
6-mo -52.05%
1-year -71.89%
3-year -79.10%
5-year -90.89%
YTD -70.95%
2020 -60.94%
2019 47.26%
2018 -64.19%
2017 74.11%
2016 -19.42%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8033 seconds.